NEXIMMUNE INC (NEXI) Stock Price, Quote, News and Overview
NASDAQ:NEXI - Nasdaq - US65344D2080 - Common Stock - Currency: USD
NEXI Quote, Performance and Key Statistics
3.93
+1.62 (+70.13%)
The current stock price of NEXI is 3.93 USD. In the past month the price increased by 35.99%. In the past year, price decreased by -41.99%.
NEXI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NEXI
Company Profile
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. The company is headquartered in Gaithersburg, Maryland and currently employs 6 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The firm is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Company Info
NEXIMMUNE INC
9119 Gaither Road
Gaithersburg MARYLAND 20878 US
CEO: Scott Carmer
Employees: 6
Company Website: https://www.neximmune.com/
Phone: 13018259810
NEXIMMUNE INC / NEXI FAQ
What is the stock price of NEXIMMUNE INC today?
The current stock price of NEXI is 3.93 USD. The price increased by 70.13% in the last trading session.
What is the ticker symbol for NEXIMMUNE INC stock?
The exchange symbol of NEXIMMUNE INC is NEXI and it is listed on the Nasdaq exchange.
On which exchange is NEXI stock listed?
NEXI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEXIMMUNE INC stock?
7 analysts have analysed NEXI and the average price target is 2.04 USD. This implies a price decrease of -48.09% is expected in the next year compared to the current price of 3.93. Check the NEXIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEXIMMUNE INC worth?
NEXIMMUNE INC (NEXI) has a market capitalization of 5.38M USD. This makes NEXI a Nano Cap stock.
How many employees does NEXIMMUNE INC have?
NEXIMMUNE INC (NEXI) currently has 6 employees.
Should I buy NEXIMMUNE INC (NEXI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NEXI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NEXI, evaluating the profitability, health, valuation and growth aspects
- NEXIMMUNE INC (NEXI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEXIMMUNE INC (NEXI) Sales and EPS estimates to see what analysts future expectations are.
- NEXIMMUNE INC (NEXI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEXIMMUNE INC (NEXI) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEXIMMUNE INC (NEXI) Stock Chart to make your own analysis
- NEXIMMUNE INC (NEXI) Latest news and press-releases to stay up to date.
Does NEXIMMUNE INC (NEXI) stock pay dividends?
NEXI does not pay a dividend.
When does NEXIMMUNE INC (NEXI) report earnings?
NEXIMMUNE INC (NEXI) will report earnings on 2024-08-07, after the market close.
What is the Price/Earnings (PE) ratio of NEXIMMUNE INC (NEXI)?
NEXIMMUNE INC (NEXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-66.25).
What is the Short Interest ratio of NEXIMMUNE INC (NEXI) stock?
The outstanding short interest for NEXIMMUNE INC (NEXI) is 0.58% of its float. Check the ownership tab for more information on the NEXI short interest.
NEXI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NEXI. When comparing the yearly performance of all stocks, NEXI is a bad performer in the overall market: 83.05% of all stocks are doing better.
NEXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NEXI. NEXI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NEXI Financial Highlights
Over the last trailing twelve months NEXI reported a non-GAAP Earnings per Share(EPS) of -66.25. The EPS decreased by -245.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -287.63% | ||
| ROE | -871.66% | ||
| Debt/Equity | 0 |
NEXI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NEXI. The Buy consensus is the average rating of analysts ratings from 7 analysts.